doxorubicin@MSN

Doxorubicin@MSN refers to a formulation in which the chemotherapeutic agent doxorubicin is loaded into mesoporous silica nanoparticles (MSNs) for targeted drug delivery. This nanoformulation is designed to enhance the selective delivery of doxorubicin to tumor cells while minimizing toxicity to normal tissues. MSNs serve as carriers that can be engineered with surface modifications such as polydopamine coatings and tumor-targeting ligands, enabling controlled and stimuli-responsive release of doxorubicin in the tumor microenvironment. The mechanism of action remains that of conventional doxorubicin—primarily inhibition of topoisomerase II leading to DNA damage and cell death—but the MSN carrier system aims to improve pharmacokinetics, reduce off-target effects, and increase therapeutic efficacy by exploiting features like pH sensitivity or redox responsiveness for on-demand drug release[2][3][6]. This approach is under preclinical investigation for various cancers.

Other names

MSN-doxorubicinDOX-loaded mesoporous silica nanoparticlesDOX@MSN